drugset
Drugs / Tovecimig
last change Aug 2026 re-read 3 minutes ago

Tovecimig

Monoclonal antibody

Developed for
colorectal cancer
Investigated by
Compass Therapeutics · Washington University School of Medicine

Trials 1

today NCT07662031 · Ph 2
2027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07662031 Aug 2026 → Aug 2030 expected colorectal cancer Washington University School of Medicine Not yet recruiting No outcome recorded

Press releases naming this drug 7 releases

DateIssuerRelease
2026-07-17 Compass Therapeutics Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 compasstherapeutics.com ↗
2026-04-27 Compass Therapeutics Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer compasstherapeutics.com ↗
2026-04-24 Compass Therapeutics Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer compasstherapeutics.com ↗
2025-04-28 Compass Therapeutics Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting compasstherapeutics.com ↗
2025-04-21 Compass Therapeutics Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer compasstherapeutics.com ↗
2025-04-01 Compass Therapeutics Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer compasstherapeutics.com ↗
2025-03-31 Compass Therapeutics Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer compasstherapeutics.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Tovecimig ClinicalTrials.gov intervention name — accepted as the source's own label NCT07662031 ↗
Modality Monoclonal antibody — CHEMBL6068308 ↗
Route Intravenous “dose intravenously” NCT07662031 ↗